Showing results (261-270 of 288) with videos related to
Sort By:
Pageof 29
Biomaterials|November 19, 2018
In vitro placenta barrier model using primary human trophoblasts, underlying connective tissue and vascular endotheliumAkihiro Nishiguchi, Catherine Gilmore, Aman Sood, et al.Head & Neck|September 12, 2020
Evaluating compliance with process-related quality metrics and survival in oral cavity squamous cell carcinoma: Multi-institutional oral cavity collaboration studySara W Liu, Neil M Woody, Wei Wei, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Lisa Licitra, Kevin Harrington, et al.The Lancet. Oncology|April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.JCO Precision Oncology|February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE StudyOlga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.Journal for Immunotherapy of Cancer|March 12, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2017
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelinesVincent Grégoire, Mererid Evans, Quynh-Thu Le, et al.Pageof 29